A Study to Evaluate Safety, Engraftment, and Efficacy of VC-01 in Subjects With T1 Diabetes Mellitus
Launched by VIACYTE · Dec 16, 2020
Trial Information
Current as of April 28, 2025
Terminated
Keywords
ClinConnect Summary
This trial will test if VC-01 combination product can be implanted and maintained with safety, tolerability, and efficacy for up to Month 12/Week 52.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Men and non-pregnant women
- • Diagnosis of T1DM for a minimum of 3 years.
- • Stable, optimized diabetic regimen
- • Acceptable candidate for implant and explant procedures.
- • Willing and able to comply with protocol requirements.
- • Meet insulin dosing requirements per protocol
- Exclusion Criteria:
- • • Advanced complications associated with diabetes
About Viacyte
ViaCyte is a pioneering biotechnology company focused on the development of innovative cell-based therapies for the treatment of diabetes. By harnessing the potential of stem cell-derived pancreatic islet cells, ViaCyte aims to restore the body’s ability to produce insulin, thus addressing the underlying causes of the disease. The company is dedicated to advancing its research through rigorous clinical trials and collaborations, driven by a commitment to improving patient outcomes and transforming diabetes care. With a team of experienced professionals, ViaCyte strives to bring novel therapeutic solutions to market, enhancing the quality of life for individuals living with diabetes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Walnut Creek, California, United States
Austin, Texas, United States
Atlanta, Georgia, United States
Escondido, California, United States
Patients applied
Trial Officials
Manasi Jaiman, MD
Principal Investigator
ViaCyte, Inc.
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials